Diagnostic definitions - Metabolic syndrome

British Journal of Diabetes and Vascular Disease

Volumn 5, Issue 3, 2005, Pages 115-118

  Day, Caroline ^a  

^a ASTON UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; GLUCOSE OXIDASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; PLACEBO; RIMONABANT; SIBUTRAMINE; TETRAHYDROLIPSTATIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ANTHROPOMETRY; BEHAVIOR MODIFICATION; BODY MASS; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DIAGNOSTIC PROCEDURE; DRUG DOSE REGIMEN; DRUG RESPONSE; DYSLIPIDEMIA; EDITORIAL; EXERCISE; GLUCOSE INTOLERANCE; HUMAN; HYPERINSULINEMIA; HYPERTENSION; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIFESTYLE; META ANALYSIS; METABOLIC SYNDROME X; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; RADIOIMMUNOASSAY; RISK ASSESSMENT; RISK FACTOR; SMOKING CESSATION; SYSTEMATIC REVIEW; TREATMENT OUTCOME; WEIGHT REDUCTION;

EID: 21644443164     PISSN: 14746514     EISSN: None     Source Type: Journal    
DOI: 10.1177/14746514050050030101     Document Type: Editorial

References (27)

1. Reaven G. The metabolic syndrome or the insulin resistance syndrome? Different names, different concepts, and different goals. Endocrinol Metab Clin N Am 2004;33:283-303.
2. Himsworth HP. Diabetes Mellitus: its differentiation into insulin-sensitive and insulin-insensitive types. Lancet 1936; Jan 18th: 5864-8.
3. Hales CN, Randle PJ. Immunoassay of insulin with insulin-antibody precipitate. Biochem J 1963;88:137-46.
4. Marks V. An improved glucose-oxidase method for determining blood, C.S.F. and urine glucose levels. Clin Chim Acta 1959; 4:395-400.
5. Reaven GM. Role of insulin resistance in human disease. Diabetes 1988; 37:1595-607.
6. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998;15:539-53.
7. WHO Consultation. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Geneva: World Health Organisation, Geneva; 1999. Report No. 99.2. (http://whqlibdoc.who.int/hq/1999/WHO_NCD_NCS_99.2.pdf)
8. Balkau B, Charles MA. Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR). Diabet Med 1999;16:442-3.
9. Grundy SM, Brewer B Jr, Cleeman JI et al. Definition of metabolic syndrome. Circulation 2004;109:433-8. (2004 guidelines at www.nhlbi.nih.gov/guidelines/cholesterol/atglance.pdf)
10. Einhorn D, Reaven GM, Cobin RH et al. American College of Endocrinology position statement on the insulin resistance syndrome. Endocr Pract 2003;9:237-52.
11. The IDF consensus worldwide definition of the metabolic syndrome, 2005 http://www.idf.org/webdata/docs/DF_Metasyndrome_definition.pdf
12. Ford ES, Wayne HG, Mokdad AH. Increasing prevalence of the metabolic syndrome among U.S. Adults. Diabetes Care 2004; 27:2444-9.
13. The DECODE Study Group. Comparison of three different definitions for the metabolic syndrome in non-diabetic Europeans. Br J Diabetes Vasc Dis 2005;5:161-8.
14. Eckel RH, Scott MG, Zimmet PZ. The metabolic syndrome. Lancet 2005; 365;1415-28.
15. Sattar N, Tan CE, Han TS et al. Associations of indices of adiposity with atherogenic lipoprotein subfractions. Int J Obes Relat Metab Disord 1998;22:432-9.
16. Goodpaster BH, Krishnaswami S, Harris TB et al. Obesity, regional body fat distribution, and the metabolic syndrome in older men and women. Arch intern Med 2005;165:777-83.
17. Paradisi G, Smith L, Burnter C et al. Dual energy X-ray absorptiometry assessment of fat mass distribution and its association with the insulin resistance syndrome. Diabetes Care 1999; 22:1310-17.
18. Wajchenberg BL. Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. Endocrine Revs 2000; 21:697-738.
19. St-Onge M-P, Janssen I, Heymsfield SB. Metabolic syndrome in North Americans. New definition of the metabolically obese, normal weight individual. Diabetes Care 2004;27:2222-8.
20. Matsuzawa Y, Shimomura I, Nakamura T, Keno Y, Kotani K, Tokunaga K. Pathophysiology and pathogenesis of visceral fat obesity. Obes Res 1995;3:187S-194S.
21. Bailey CJ, Day C. New pharmacological approaches to obesity. Obesity in Practice 2005;1:2-5.
22. Padwal R, Li SK, Lau DC. Long-term pharmacotherapy for overweight and obesity: a systematic review and meta-analysis of randomized controlled trials. Int J Obes Relat Metab Disord 2003; 27:1437-46.
23. Day C, Bailey CJ. Sibutramine update. Br J Diabetes Vasc Dis 2002;2: 392-7.
24. Wirth A. Reduction of body weight and co-morbidities by orlistat: The XXL-Primary Health Care Trial. Diabetes Obesity Metabol 2004;7:21-7.
25. Finer N, Pagotto U. The endocannabinoid system: a new therapeutic target for cardiovascular risk factor management. Br J Diabetes Vasc Dis 2005;5:121-4.
26. Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rossner S; RIO-Europe Study Group. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 7-year experience from the RIO-Europe study. Lancet 2005; 365:1389-97.
27. STRATUS - US study results announced at American College of Cardiology Annual Meeting, New Orleans, March 9 2004. Press release, www.sanofi-synthelabo.com